Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 June 2024
Caval valve implantation for tricuspid regurgitationStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 21 August 2024
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 5 December 2024
Transcatheter aortic valve implantation for native aortic valve regurgitationStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 11 June 2025
Insertion of neo-chordae into the beating heart for mitral regurgitationStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Transcatheter Tricuspid Valve ReplacementStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Cor-Knot for tying suture knots in valve surgeryStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
microINR for anticoagulation therapy MT592 (MIB257)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy TSID 12037Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC